The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Pantoprazole sodium is a proton pump inhibitor reduces stomach acid
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial) have an estimated market size of US$ 48 million for twelve months ending December 2024 according to IQVIA
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
The pooled prevalence of GERD in the Indian population is 15.6 %
Subscribe To Our Newsletter & Stay Updated
